Radiology Unit, Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Hospital, University of Bologna, Via Albertoni 15, 40138, Bologna, Italy.
Unit of Internal Medicine, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Med Oncol. 2020 Mar 12;37(4):23. doi: 10.1007/s12032-020-01348-y.
Hepatocellular carcinoma (HCC), the most common primary liver neoplasia, represents the fifth most common malignant disease in men. Percutaneous ablation treatment is recommended among the treatments suggested for HCC patients in the very early/early stage. In the last decade, very important results in terms of survival benefits have been obtained with local ablative therapies, also outside the standard indications, thanks to many technical innovations. In particular, important results of ablation as a safe and effective technique have been obtained in the treatment of intermediate- or advanced-stage patients with HCC, and in the treatment of unfavourable tumour locations. Moreover, awareness is growing regarding the necessity of overcoming the rigidity of traditional guidelines in the treatment of HCC due to the complexity of patients with HCC, focusing on Precision Medicine. In this context, it is important to know the standard and non-standard indications of ablation in the treatment of HCC in order to offer the best therapeutic option tailored for each patient. The aim of this study was to analyse the possible clinical applications of ablative therapies for HCC patients, beyond the traditional indications recommended in the most widespread clinical practice guidelines for the management of HCC.
肝细胞癌（HCC）是最常见的原发性肝脏肿瘤，是男性中第五种最常见的恶性疾病。对于非常早期/早期 HCC 患者，建议采用经皮消融治疗。在过去十年中，由于许多技术创新，局部消融治疗在标准适应证之外也取得了非常重要的生存获益结果。特别是，消融作为一种安全有效的技术，在治疗中晚期 HCC 患者和治疗不利肿瘤部位方面取得了重要结果。此外，由于 HCC 患者的复杂性，人们越来越意识到需要克服传统治疗 HCC 指南的僵化性，关注精准医学。在这种情况下，了解消融治疗 HCC 的标准和非标准适应证非常重要，以便为每位患者提供最佳的治疗选择。本研究的目的是分析消融治疗 HCC 患者的可能临床应用，超出了最广泛的 HCC 管理临床实践指南中推荐的传统适应证。
